GSK Scripted Response For Wellbutrin Probe, Atty Says
GlaxoSmithKline PLC's in-house legal team planned to "script" a response to regulators if quizzed about nondisclosed information in a probe of the drugmaker's marketing of antidepressant Wellbutrin, a GSK attorney told...To view the full article, register now.
Already a subscriber? Click here to view full article